Evidence map›Paper›PMID 25604082›Full record

ArticleJournal of medical genetics2015

Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma.

Justin Rendleman, Matjaz Vogelsang, Anuj Bapodra, Christina Adaniel, Ines Silva, Duane Moogk, Carlos N Martinez, Nathaniel Fleming, Jerry Shields, Richard Shapiro and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. The Immunogenetics of Melanoma.Advances in experimental medicine and biology · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  10. Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Justin RendlemanPerlmutter Cancer Center, New York University School of Medicine, New York, USA Departments of Population Health and Environmental Medicine, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA.
Matjaz VogelsangPerlmutter Cancer Center, New York University School of Medicine, New York, USA Departments of Population Health and Environmental Medicine, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA.
Anuj BapodraPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Pathology, New York University School of Medicine, New York, USA.
Christina AdanielPerlmutter Cancer Center, New York University School of Medicine, New York, USA Department of Medicine, New York University School of Medicine, New York, USA.
Ines SilvaThe Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Medicine, New York University School of Medicine, New York, USA Ronald O. Perelman Department of Dermatology, New York University, New York, USA.
Duane MoogkPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Pathology, New York University School of Medicine, New York, USA.
Carlos N MartinezPerlmutter Cancer Center, New York University School of Medicine, New York, USA Departments of Population Health and Environmental Medicine, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA.
Nathaniel FlemingPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA.
Jerry ShieldsPerlmutter Cancer Center, New York University School of Medicine, New York, USA Department of Medicine, New York University School of Medicine, New York, USA.
Richard ShapiroThe Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Surgery, New York University School of Medicine, New York, USA.
Russell BermanThe Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Surgery, New York University School of Medicine, New York, USA.
Anna PavlickPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Medicine, New York University School of Medicine, New York, USA Ronald O. Perelman Department of Dermatology, New York University, New York, USA.
David PolskyPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Ronald O. Perelman Department of Dermatology, New York University, New York, USA.
Yongzhao ShaoDepartments of Population Health and Environmental Medicine, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA.
Iman OsmanPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Medicine, New York University School of Medicine, New York, USA Ronald O. Perelman Department of Dermatology, New York University, New York, USA.
Michelle KrogsgaardPerlmutter Cancer Center, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA Department of Pathology, New York University School of Medicine, New York, USA.
Tomas KirchhoffPerlmutter Cancer Center, New York University School of Medicine, New York, USA Departments of Population Health and Environmental Medicine, New York University School of Medicine, New York, USA The Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, USA.
Eastern Cooperative Oncology Group · USNew York University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
The germline variation in immune and epigenetic pathways and melanoma prognosisR21CA184924 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIRCHHOFF, TOMAS · 2013 to 2013
$169k
NCI NIH HHS 1R21CA184924-01NCI NIH HHS P30 CA016087NCI NIH HHS P30CA016087NCI NIH HHS R21 CA184924
6 · The paper itself

Abstract

backgroundDue to high melanoma immunogenicity, germline genetic variants in immune pathways have been studied for association with melanoma prognosis. However, limited candidate selection, inadequate power, or lack of independent validation have hampered the reproducibility of these prior findings, preventing personalised clinical applicability in melanoma prognostication. Our objective was to assess the prognostic utility of genetic variants in immunomodulatory pathways for prediction of melanoma clinical outcomes.

methodsWe genotyped 72 tag single nucleotide polymorphisms (SNPs) in 44 immunomodulatory genes in a population sample of 1022 melanoma patients and performed Cox regression analysis to test the association between SNPs and melanoma recurrence-free (RFS) and overall survival (OS). We have further investigated the most significant associations using a fine mapping strategy and followed with functional analyses in CD4+ T cells in a subset of 75 melanoma patients.

resultsThe most significant associations were found with melanoma OS for rs3024493 in IL10 at chromosome 1q32.1 (heterozygous HR 0.58, 95% CI 0.39 to 0.86; p=0.0006), a variant previously shown to be linked with autoimmune conditions. Multiple additional SNPs at 1q32.1 were also nominally associated with OS confirming at least two independent association signals in this locus. In addition, we found rs3024493 associated with the downregulation of interleukin 10 (IL10) secretion in CD4+ T cells.

conclusionsWe discovered novel associations of IL10 with melanoma survival at 1q32.1, suggesting this locus should be considered as a novel melanoma prognostic biomarker with potential for aiding melanoma patient management. Our findings also provide further support for an alternative role of IL10 in stimulation of anti-tumour immune response.

Indexed as

Chromosomes, Human, Pair 1AdolescentAdultAgedAged, 80 and overCutaneous Malignant MelanomaDisease-Free SurvivalFemaleHumansImmunomodulationInterleukin-10InterleukinsMaleMelanomaMiddle AgedPolymorphism, Single NucleotideIL10 protein, humanInterleukin-10Interleukinsimmune responsemelanomaSNPsurvival

Identifiers

PMID25604082
PMCPMC5166523
OpenAlexW2101572568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.